Dr. Jeffrey Glassberg is currently an Assistant Professor of Emergency Medicine, Hematology and Medical Oncology at Mount Sinai School of Medicine. He obtained his MD and a Masters’ degree in clinical research at Washington University in St. Louis School of Medicine in 2006. Dr. Glassberg completed his emergency medicine residency at NYU/Bellevue in 2010, followed by a research fellowship at Mount Sinai in July of 2012. Currently, Dr. Glassberg is funded by the National Heart Lung and Blood Institute by a K23 career development award and also holds an appointment at Rockefeller University as a visiting scientist. Dr. Glassberg has become a leader in promoting evidence based strategies for the acute management of Sickle Cell Disease. He has several research focuses within Sickle Cell including pulmonary complications of Sickle Cell Disease, novel biomarkers for vaso-occlusive crises, and novel agents for the prevention and treatment of vaso-occlusion. In addition to practicing as an attending in the ED, Dr. Glassberg also sees patients in Sickle Cell clinic and serves as the primary physician for many patients with Sickle Cell disease who are at Mount Sinai. He is also active regionally and nationally as a member of the Queens Sickle Cell Advocacy Network, the New York Sickle Cell Advisory Council and the Sickle Cell Disease Association of America.
Regional / National Committees / Advisory Boards:
New York State Sickle Cell Advisory Committee
Board of Directors, Queens Sickle Cell Advisory Committee
Medical and Research Advisory Committee: Sickle Cell Disease Association of America
2012 – present Pain Committee, Mount Sinai Health System
American Board of Emergency Medicine
MD, Washington University
Internship, Emergency Medicine
Residency, Emergency Medicine
Adhesion Molecule Expression on Peripheral Blood Cells of Patients with Sickle Cell Anemia Compared to Normal Controls and Patients with B-thalassemia
The purpose of this study is to compare the stickiness of blood cells of patients with sickle cell anemia to normal controls and patients with another inherited blood disorder called ß-thalassemia.
Glassberg JA, Strunk R, DeBaun MR. Wheezing in children with sickle cell disease. Current opinion in pediatrics 2014 Feb; 26(1).
Glassberg JA, Tanabe P, Chow A, Harper K, Haywood C, DeBaun MR, Richardson LD. Emergency provider analgesic practices and attitudes toward patients with sickle cell disease. Annals of emergency medicine 2013 Oct; 62(4).
Glassberg J, Simon J, Patel N, Jeong JM, McNamee JJ, Yu G. Derivation and preliminary validation of a risk score to predict 30-day ED revisits for sickle cell pain. The American journal of emergency medicine 2015 Oct; 33(10).
Perry M, Simon J, Gareau D, Glassberg J. Bayesian analyses demonstrate tissue blood volume is not decreased during acute sickle cell pain episodes: A preliminary study. Clinical hemorheology and microcirculation 2015 Jan;.
Glassberg J, Spivey JF, Strunk R, Boslaugh S, DeBaun MR. Painful episodes in children with sickle cell disease and asthma are temporally associated with respiratory symptoms. Journal of pediatric hematology/oncology 2006 Aug; 28(8).
Field JJ, Glassberg J, Gilmore A, Howard J, Patankar S, Yan Y, Davies SC, Debaun MR, Strunk RC. Longitudinal analysis of pulmonary function in adults with sickle cell disease. American journal of hematology 2008 Jul; 83(7).
Glassberg JA, Chow A, Wisnivesky J, Hoffman R, Debaun MR, Richardson LD. Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity. British journal of haematology 2012 Nov; 159(4).
Diep RT, Busani S, Simon J, Punzalan A, Skloot GS, Glassberg JA. Cough and wheeze events are temporally associated with increased pain in individuals with sickle cell disease without asthma. British journal of haematology 2015 Sep; 170(5).
Glassberg J. Evidence-based management of sickle cell disease in the emergency department. Emergency medicine practice 2011 Aug; 13(8).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Glassberg did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.